Palvella Therapeutics, Inc.

Stage 3 · Topping · week 2

As of Oct 22, 2026, Palvella Therapeutics is in Stage 3, the topping phase, now in week 2 (since Oct 9, 2026). It closed at $126.39, 20.1% below its 52-week high and above its 200-day average, which is rising.

$126.39

+1.93% today

$1.8B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is PVLA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 19w

S4 14w

S3 15w

S2 13w

S2 30w

S2 13w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 5w → S1 6w → S4 19w → S1 5w → S4 14w → S1 4w → S2 9w → S3 15w → S2 13w → S3 7w → S2 30w → S3 3w → S2 12w → S3 6w → S2 13w → S3 2w current

Total tracked: 165 weeks across 16 stage runs.

PVLA among Biotechnology69th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…69	PVLAPalvella Therapeutics, Inc.	Stage 3 · wk 2	91	−15.5%

vs 52W High

-20.1%

$70.43 lo$158.13 hi

20.1% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 2

1w13w26w

Week 2, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

0.5%

200 DMA: $125.77 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.47x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-15.5%

-8.4%

-0.5%

YTD

+26.0%

+67.1%

Scan Membership

Breakout Watch

Latest: 2025-02-25

5 appearances in last 60 days. First seen: 2019-06-21.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 2 · Vol 0.47x

2026-10-21S3

Wk 2 · Vol 1.08x

2026-10-20S3

Wk 2 · Vol 1.23x

2026-10-19S3

Wk 2 · Vol 1.27x

2026-10-16S3

Wk 2 · Vol 0.85x

2026-10-15S3

Wk 1 · Vol 1.15x

2026-10-14S3

Wk 1 · Vol 1.84x

2026-10-13S3

Wk 1 · Vol 1.04x

2026-10-12S3

Wk 1 · Vol 1.03x

2026-10-09S32→3

Wk 1 · Vol 0.84x

2026-10-08S2

Wk 14 · Vol 1.02x

2026-10-07S2

Wk 13 · Vol 0.74x

Moving averages & range

50 DMA

$143.01

200 DMA

$125.77

52W High

$158.13

52W Low

$70.43

5D Low

$120.30

Resistance levels (recent highs)

20d High

$139.83

60d High

$158.13

120d High

$158.13

250d High

$158.13

Next resistance

+10.6%

to 20d High

ROE

-46.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 8.4

Palvella Therapeutics: quick answers

What stage is Palvella Therapeutics in?

As of Oct 22, 2026, Palvella Therapeutics (PVLA) is in Stage 3, the topping phase. It entered Stage 3 on Oct 9, 2026 and is in week 2. What the four stages mean

Is Palvella Therapeutics in an uptrend?

Its uptrend has stalled. Palvella Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 0.5% above its 200-day average, which is rising.

How far is Palvella Therapeutics from its 52-week high?

Palvella Therapeutics closed at $126.39 on Oct 22, 2026, 20.1% below its 52-week high of $158.13. Its 52-week low is $70.43.

How has Palvella Therapeutics performed over the past year?

As of Oct 22, 2026, Palvella Therapeutics is up 67.1% over the past year and up 26.0% so far in 2026.

Which sector and industry is Palvella Therapeutics in?

Palvella Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.